9 results on '"Matthew W. Ellis"'
Search Results
2. Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy
- Author
-
Muhammad Riaz, Jinkyu Park, Lorenzo R. Sewanan, Yongming Ren, Jonas Schwan, Subhash K. Das, Pawel T. Pomianowski, Yan Huang, Matthew W. Ellis, Jiesi Luo, Juli Liu, Loujin Song, I-Ping Chen, Caihong Qiu, Masayuki Yazawa, George Tellides, John Hwa, Lawrence H. Young, Lei Yang, Charles C. Marboe, Daniel L. Jacoby, Stuart G. Campbell, and Yibing Qyang
- Subjects
Physiology (medical) ,Mutation ,Cardiomyopathy, Hypertrophic, Familial ,Humans ,Muscle Proteins ,Myocytes, Cardiac ,Actomyosin ,Cardiomyopathy, Hypertrophic ,LIM Domain Proteins ,Cardiology and Cardiovascular Medicine ,Mechanotransduction, Cellular ,Article - Abstract
Background: Familial hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and is typically caused by mutations in genes encoding sarcomeric proteins that regulate cardiac contractility. HCM manifestations include left ventricular hypertrophy and heart failure, arrythmias, and sudden cardiac death. How dysregulated sarcomeric force production is sensed and leads to pathological remodeling remains poorly understood in HCM, thereby inhibiting the efficient development of new therapeutics. Methods: Our discovery was based on insights from a severe phenotype of an individual with HCM and a second genetic alteration in a sarcomeric mechanosensing protein. We derived cardiomyocytes from patient-specific induced pluripotent stem cells and developed robust engineered heart tissues by seeding induced pluripotent stem cell–derived cardiomyocytes into a laser-cut scaffold possessing native cardiac fiber alignment to study human cardiac mechanobiology at both the cellular and tissue levels. Coupled with computational modeling for muscle contraction and rescue of disease phenotype by gene editing and pharmacological interventions, we have identified a new mechanotransduction pathway in HCM, shown to be essential in modulating the phenotypic expression of HCM in 5 families bearing distinct sarcomeric mutations. Results: Enhanced actomyosin crossbridge formation caused by sarcomeric mutations in cardiac myosin heavy chain ( MYH7 ) led to increased force generation, which, when coupled with slower twitch relaxation, destabilized the MLP (muscle LIM protein) stretch-sensing complex at the Z-disc. Subsequent reduction in the sarcomeric muscle LIM protein level caused disinhibition of calcineurin–nuclear factor of activated T-cells signaling, which promoted cardiac hypertrophy. We demonstrate that the common muscle LIM protein–W4R variant is an important modifier, exacerbating the phenotypic expression of HCM, but alone may not be a disease-causing mutation. By mitigating enhanced actomyosin crossbridge formation through either genetic or pharmacological means, we alleviated stress at the Z-disc, preventing the development of hypertrophy associated with sarcomeric mutations. Conclusions: Our studies have uncovered a novel biomechanical mechanism through which dysregulated sarcomeric force production is sensed and leads to pathological signaling, remodeling, and hypertrophic responses. Together, these establish the foundation for developing innovative mechanism-based treatments for HCM that stabilize the Z-disc MLP-mechanosensory complex.
- Published
- 2022
- Full Text
- View/download PDF
3. Epigallocatechin gallate facilitates extracellular elastin fiber formation in induced pluripotent stem cell derived vascular smooth muscle cells for tissue engineering
- Author
-
Matthew W. Ellis, Muhammad Riaz, Yan Huang, Christopher W. Anderson, Jiesi Luo, Jinkyu Park, Colleen A. Lopez, Luke D. Batty, Kimberley H. Gibson, and Yibing Qyang
- Subjects
Tissue Engineering ,Induced Pluripotent Stem Cells ,Myocytes, Smooth Muscle ,Humans ,Reproducibility of Results ,Cardiology and Cardiovascular Medicine ,Molecular Biology ,Article ,Catechin ,Muscle, Smooth, Vascular ,Elastin - Abstract
Tissue engineered vascular grafts possess several advantages over synthetic or autologous grafts, including increased availability and reduced rates of infection and thrombosis. Engineered grafts constructed from human induced pluripotent stem cell derivatives further offer enhanced reproducibility in graft production. One notable obstacle to clinical application of these grafts is the lack of elastin in the vessel wall, which would serve to endow compliance in addition to mechanical strength. This study establishes the ability of the polyphenol compound epigallocatechin gallate, a principal component of green tea, to facilitate the extracellular formation of elastin fibers in vascular smooth muscle cells derived from human induced pluripotent stem cells. Further, this study describes the creation of a doxycycline-inducible elastin expression system to uncouple elastin production from vascular smooth muscle cell proliferative capacity to permit fiber formation in conditions conducive to robust tissue engineering.
- Published
- 2022
- Full Text
- View/download PDF
4. Readily Available Tissue-Engineered Vascular Grafts Derived From Human Induced Pluripotent Stem Cells
- Author
-
Jiesi Luo, Lingfeng Qin, Jinkyu Park, Mehmet H. Kural, Yan Huang, Xiangyu Shi, Muhammad Riaz, Juan Wang, Matthew W. Ellis, Christopher W. Anderson, Yifan Yuan, Yongming Ren, Mervin C. Yoder, George Tellides, Laura E. Niklason, and Yibing Qyang
- Subjects
Tissue Engineering ,Tissue Scaffolds ,Physiology ,Induced Pluripotent Stem Cells ,Humans ,Cell Differentiation ,Cardiology and Cardiovascular Medicine ,Article ,Blood Vessel Prosthesis - Published
- 2022
- Full Text
- View/download PDF
5. Efficient Differentiation of Human Induced Pluripotent Stem Cells into Endothelial Cells under Xenogeneic-free Conditions for Vascular Tissue Engineering
- Author
-
Christopher W. Anderson, Yifan Yuan, Juan Wang, Mehmet H. Kural, Yuyao Lin, Jiesi Luo, Xiangyu Shi, Matthew W. Ellis, Yibing Qyang, Muhammad Riaz, Laura E. Niklason, and Shang-Min Zhang
- Subjects
Induced Pluripotent Stem Cells ,0206 medical engineering ,Cell ,Biomedical Engineering ,02 engineering and technology ,Biochemistry ,Article ,Biomaterials ,Immune system ,medicine ,Animals ,Humans ,Human Induced Pluripotent Stem Cells ,Molecular Biology ,Tissue engineered ,Decellularization ,Tissue Engineering ,Chemistry ,Endothelial Cells ,Cell Differentiation ,General Medicine ,021001 nanoscience & nanotechnology ,020601 biomedical engineering ,In vitro ,Blood Vessel Prosthesis ,Cell biology ,medicine.anatomical_structure ,Time course ,Vascular tissue engineering ,0210 nano-technology ,Biotechnology - Abstract
Tissue engineered vascular grafts (TEVGs) represent a promising therapeutic option for emergency vascular intervention. Although the application of small-diameter TEVGs using patient-specific primary endothelial cells (ECs) to prevent thrombosis and occlusion prior to implantation could be hindered by the long time course required for in vitro endothelialization, human induced pluripotent stem cells (hiPSCs) provide a robust source to derive immunocompatible ECs (hiPSC-ECs) for immediate TEVG endothelialization. To achieve clinical application, hiPSC-ECs should be derived under culture conditions without the use of animal-derived reagents (xenogeneic-free conditions), to avoid unwanted host immune responses from xenogeneic reagents. However, a completely xenogeneic-free method of hiPSC-EC generation has not previously been established. Herein, we substituted animal-derived reagents used in a standard method of xenogeneic hiPSC-EC differentiation with functional counterparts of human origin. As a result, we generated xenogeneic-free hiPSC-ECs (XF-hiPSC-ECs) with similar marker expression and function to those of human primary ECs. Furthermore, XF-hiPSC-ECs functionally responded to shear stress with typical cell alignment and gene expression. Finally, we successfully endothelialized decellularized human vessels with XF-hiPSC-ECs in a dynamic bioreactor system. In conclusion, we developed xenogeneic-free conditions for generating functional hiPSC-ECs suitable for vascular tissue engineering, which will further move TEVG therapy toward clinical application.
- Published
- 2021
- Full Text
- View/download PDF
6. Xenogeneic-free generation of vascular smooth muscle cells from human induced pluripotent stem cells for vascular tissue engineering
- Author
-
George Tellides, Laura E. Niklason, Jiesi Luo, Mehmet H. Kural, Xiangyu Shi, Yuyao Lin, Matthew W. Ellis, Muhammad Riaz, Guangxin Li, Christopher W. Anderson, and Yibing Qyang
- Subjects
Vascular smooth muscle ,0206 medical engineering ,Induced Pluripotent Stem Cells ,Myocytes, Smooth Muscle ,Biomedical Engineering ,02 engineering and technology ,Biochemistry ,Muscle, Smooth, Vascular ,Article ,Biomaterials ,Mice ,VSMC differentiation ,Mechanical strength ,Animals ,Humans ,Human Induced Pluripotent Stem Cells ,Induced pluripotent stem cell ,Molecular Biology ,Vascular tissue ,Tissue Engineering ,Chemistry ,Cell Differentiation ,General Medicine ,021001 nanoscience & nanotechnology ,musculoskeletal system ,020601 biomedical engineering ,Cell biology ,Vascular tissue engineering ,cardiovascular system ,0210 nano-technology ,Biotechnology - Abstract
Development of mechanically advanced tissue-engineered vascular grafts (TEVGs) from human induced pluripotent stem cell (hiPSC)-derived vascular smooth muscle cells (hiPSC-VSMCs) offers an innovative approach to replace or bypass diseased blood vessels. To move current hiPSC-TEVGs toward clinical application, it is essential to obtain hiPSC-VSMC-derived tissues under xenogeneic-free conditions, meaning without the use of any animal-derived reagents. Many approaches in VSMC differentiation of hiPSCs have been reported, although a xenogeneic-free method for generating hiPSC-VSMCs suitable for vascular tissue engineering has yet to be established. Based on our previously established standard method of xenogeneic VSMC differentiation, we have replaced all animal-derived reagents with functional counterparts of human origin and successfully derived functional xenogeneic-free hiPSC-VSMCs (XF-hiPSC-VSMCs). Next, our group developed tissue rings via cellular self-assembly from XF-hiPSC-VSMCs, which exhibited comparable mechanical strength to those developed from xenogeneic hiPSC-VSMCs. Moreover, by seeding XF-hiPSC-VSMCs onto biodegradable polyglycolic acid (PGA) scaffolds, we generated engineered vascular tissues presenting effective collagen deposition which were suitable for implantation into an immunodeficient mice model. In conclusion, our xenogeneic-free conditions for generating hiPSC-VSMCs produce cells with the comparable capacity for vascular tissue engineering as standard xenogeneic protocols, thereby moving the hiPSC-TEVG technology one step closer to safe and efficacious clinical translation.
- Published
- 2020
7. Acetyl‐CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents
- Author
-
Ricardo Ramirez, Adrian S. Ray, Ting Wang, Matthew W. Ellis, Gary W. Cline, Li Li, Daniel F. Vatner, Dongyan Zhang, Gerald I. Shulman, Kari E. Wong, Rachel J. Perry, Leigh Goedeke, Jamie Bates, and Carine Beysen
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Receptors, Cytoplasmic and Nuclear ,Fatty Acids, Nonesterified ,Lipoproteins, VLDL ,Article ,Rats, Sprague-Dawley ,03 medical and health sciences ,chemistry.chemical_compound ,Insulin resistance ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Nonalcoholic fatty liver disease ,Ketogenesis ,medicine ,Animals ,PPAR alpha ,Triglycerides ,Fatty acid synthesis ,Lipoprotein lipase ,Fenofibrate ,Hepatology ,Lipogenesis ,Acetyl-CoA carboxylase ,Ketones ,medicine.disease ,Metabolic Flux Analysis ,030104 developmental biology ,Endocrinology ,Liver ,chemistry ,Insulin Resistance ,Acetyl-CoA Carboxylase ,medicine.drug - Abstract
Pharmacologic inhibition of acetyl-CoA carboxylase (ACC) enzymes, ACC1 and ACC2, offers an attractive therapeutic strategy for nonalcoholic fatty liver disease (NAFLD) through simultaneous inhibition of fatty acid synthesis and stimulation of fatty acid oxidation. However, the effects of ACC inhibition on hepatic mitochondrial oxidation, anaplerosis, and ketogenesis in vivo are unknown. Here, we evaluated the effect of a liver-directed allosteric inhibitor of ACC1 and ACC2 (Compound 1) on these parameters, as well as glucose and lipid metabolism, in control and diet-induced rodent models of NAFLD. Oral administration of Compound 1 preferentially inhibited ACC enzymatic activity in the liver, reduced hepatic malonyl-CoA levels, and enhanced hepatic ketogenesis by 50%. Furthermore, administration for 6 days to high-fructose-fed rats resulted in a 20% reduction in hepatic de novo lipogenesis. Importantly, long-term treatment (21 days) significantly reduced high-fat sucrose diet-induced hepatic steatosis, protein kinase C epsilon activation, and hepatic insulin resistance. ACCi treatment was associated with a significant increase in plasma triglycerides (approximately 30% to 130%, depending on the length of fasting). ACCi-mediated hypertriglyceridemia could be attributed to approximately a 15% increase in hepatic very low-density lipoprotein production and approximately a 20% reduction in triglyceride clearance by lipoprotein lipase (P ≤ 0.05). At the molecular level, these changes were associated with increases in liver X receptor/sterol response element-binding protein-1 and decreases in peroxisome proliferator-activated receptor-α target activation and could be reversed with fenofibrate co-treatment in a high-fat diet mouse model. Conclusion: Collectively, these studies warrant further investigation into the therapeutic utility of liver-directed ACC inhibition for the treatment of NAFLD and hepatic insulin resistance.
- Published
- 2018
- Full Text
- View/download PDF
8. Vascular smooth muscle cells derived from inbred swine induced pluripotent stem cells for vascular tissue engineering
- Author
-
Jiesi Luo, Stuart G. Campbell, Yibing Qyang, David H. Sachs, Alan Dardik, Marsha W. Rolle, Liqiong Gui, Peining Li, George Tellides, Xiaoqiang Cong, Xia Li, Darrell N. Kotton, Laura E. Niklason, Lingfeng Qin, Jordan S. Pober, Matthew W. Ellis, Jonas Schwan, Yongming Ren, Mehmet H. Kural, Guangxin Li, Robert J. Hawley, and Oscar Bartulos
- Subjects
Male ,0301 basic medicine ,Vascular smooth muscle ,Swine ,Induced Pluripotent Stem Cells ,Myocytes, Smooth Muscle ,Biophysics ,Miniature swine ,Bioengineering ,Ascorbic Acid ,Biology ,Article ,Muscle, Smooth, Vascular ,Cell Line ,Biomaterials ,Mice ,03 medical and health sciences ,medicine ,Animals ,Humans ,Induced pluripotent stem cell ,Vascular tissue ,Doxycycline ,Tissue Engineering ,Tissue Scaffolds ,Vascular disease ,Endothelial Cells ,Cell Differentiation ,Fibroblasts ,Ascorbic acid ,medicine.disease ,Coronary Vessels ,Cell biology ,HEK293 Cells ,030104 developmental biology ,Mechanics of Materials ,Immunology ,Ceramics and Composites ,Reprogramming ,Polyglycolic Acid ,Muscle Contraction ,medicine.drug - Abstract
Development of autologous tissue-engineered vascular constructs using vascular smooth muscle cells (VSMCs) derived from human induced pluripotent stem cells (iPSCs) holds great potential in treating patients with vascular disease. However, preclinical, large animal iPSC-based cellular and tissue models are required to evaluate safety and efficacy prior to clinical application. Herein, swine iPSC (siPSC) lines were established by introducing doxycycline-inducible reprogramming factors into fetal fibroblasts from a line of inbred Massachusetts General Hospital miniature swine that accept tissue and organ transplants without immunosuppression within the line. Highly enriched, functional VSMCs were derived from siPSCs based on addition of ascorbic acid and inactivation of reprogramming factor via doxycycline withdrawal. Moreover, siPSC-VSMCs seeded onto biodegradable polyglycolic acid (PGA) scaffolds readily formed vascular tissues, which were implanted subcutaneously into immunodeficient mice and showed further maturation revealed by expression of the mature VSMC marker, smooth muscle myosin heavy chain. Finally, using a robust cellular self-assembly approach, we developed 3D scaffold-free tissue rings from siPSC-VSMCs that showed comparable mechanical properties and contractile function to those developed from swine primary VSMCs. These engineered vascular constructs, prepared from doxycycline-inducible inbred siPSCs, offer new opportunities for preclinical investigation of autologous human iPSC-based vascular tissues for patient treatment.
- Published
- 2017
- Full Text
- View/download PDF
9. Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs
- Author
-
Mehmet H. Kural, Yibing Qyang, Muhammad Riaz, Guangxin Li, Liqiong Gui, Jiesi Luo, Laura E. Niklason, Stuart G. Campbell, Liping Zhao, Colleen A. Lopez, Alan Dardik, Lingfeng Qin, Yifan Yuan, Shang Min Zhang, George Tellides, J. Alexander Clark, Xiaoqiang Cong, Juan Wang, Shun Ono, Matthew W. Ellis, Yan Huang, and Akitsu Hotta
- Subjects
0303 health sciences ,Tissue engineered ,Vascular smooth muscle ,Pulsatile flow ,Cell Biology ,Biology ,03 medical and health sciences ,0302 clinical medicine ,Biodegradable scaffold ,Mechanical strength ,Genetics ,Molecular Medicine ,Report generation ,Human Induced Pluripotent Stem Cells ,Induced pluripotent stem cell ,030217 neurology & neurosurgery ,030304 developmental biology ,Biomedical engineering - Abstract
Summary Vascular smooth muscle cells (VSMCs) can be derived in large numbers from human induced pluripotent stem cells (hiPSCs) for producing tissue-engineered vascular grafts (TEVGs). However, hiPSC-derived TEVGs are hampered by low mechanical strength and significant radial dilation after implantation. Here, we report generation of hiPSC-derived TEVGs with mechanical strength comparable to native vessels used in arterial bypass grafts by utilizing biodegradable scaffolds, incremental pulsatile stretching, and optimal culture conditions. Following implantation into a rat aortic model, hiPSC-derived TEVGs show excellent patency without luminal dilation and effectively maintain mechanical and contractile function. This study provides a foundation for future production of non-immunogenic, cellularized hiPSC-derived TEVGs composed of allogenic vascular cells, potentially serving needs to a considerable number of patients whose dysfunctional vascular cells preclude TEVG generation via other methods.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.